Compare Apollo Global Management Ord Shs (APO) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs BridgeBio Pharma Inc — how do they compare? Apollo Global Management Ord Shs trades at $118.99 (market cap $69.38B), while BridgeBio Pharma Inc trades at $83.01 (market cap $16.81B). The key difference: Apollo Global Management Ord Shs is far larger — about 4.1× BridgeBio Pharma Inc's market cap, and Apollo Global Management Ord Shs pays a 1.87% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| APO | BBIO | |
|---|---|---|
Market Cap | $69.38B | $16.81B |
Sector | Financials | Health |
52-Week High | $156.05 | $90.17 |
52-Week Low | $100.30 | $44.81 |
Enterprise Value | -$168.19B | $18.36B |
Dividend Yield | 1.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $118.83, down 1.25% today, with a bearish technical signal despite strong analyst support. The company reported Q1 2026 EPS of $1.94, beating estimates, and maintains robust revenue of $32.05B for 2025. However, net income margin compressed to 3.63%, and ROE is negative at -1.34%. Recent news highlights private credit sector growth but also liquidity concerns as APO capped withdrawals from its $25B fund after 16.8% redemption requests in June 2026.
APO's outlook is mixed: strong fundraising and capital deployment in private credit offer growth potential, with an average analyst price target of $149.71 implying 26% upside. Risks include liquidity pressures in private credit funds, ongoing legal investigations, and sensitivity to economic cycles. The stock's high P/E of 75.69 requires sustained earnings growth to justify valuation.
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth to $502.08M in 2025, yet remains unprofitable with a net income margin of -124.41%. Recent news highlights regulatory progress for its drug pipeline, including Attruby's commercial momentum and multiple NDA submissions, driving investor optimism despite consistent quarterly EPS misses.
The outlook hinges on successful drug launches and pipeline execution to achieve profitability, with a consensus price target of $104.57 implying 26% upside. Key risks include high cash burn, dependence on Attruby's success, and competitive pressures in rare disease treatments. Analyst sentiment is overwhelmingly bullish (92% buy ratings), but the negative equity and persistent losses warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
